| Standard Multiplex PCR (n = 362) | Rapid PCR (n = 122) | P-value* |
---|---|---|---|
Demographics | |||
 Age (median years) (IQR**) | 74 (51–84) | 69 (43–84) | 0.28 |
Gender | Â | Â | 0.84 |
 Male (n) (%) | 178 (49%) | 62 (51%) |  |
 Female (n) (%) | 184 (51%) | 60 (49%) |  |
Charlson Comorbidity Index (median score) (IQR) | 1 (0–2) | 0 (0–2) | 0.09 |
Deaths (n) (%) | 6 (2%) | 2 (2%) | 0.68 |
Result availability | |||
 Test result turnaround time (median hours) (IQR) | 22.9 (16.8–38.0) | 2.6 (2.0–3.8) | < 0.01 |
Discharged from ED (n) (%) | 110 (30%) | 33 (27%) | 0.56 |
Inpatient admission (n) (%) | 252 (70%) | 89 (73%) | Â |
Length of Stay (LOS) | |||
 Discharged from ED (median days) (IQR) | 0.22 (0.15–0.44) | 0.25 (0.18–0.31) | 0.90 |
 Inpatient admission (median days) (IQR) | 5.32 (2.88–11.01) | 5.16 (2.72–8.18) | 0.72 |
Antimicrobial use |  |  | < 0.01 |
 Prescribed (n) (%) | 241 (67%) | 62 (51%) |  |
 Not prescribed (n) (%) | 121 (33%) | 60 (49%) |  |
Oseltamivir use | Â | Â | 0.02 |
 Prescribed (n) (%) | 203 (56%) | 84 (69%) |  |
 Not prescribed (n) (%) | 159 (44%) | 38 (31%) |  |
High risk patients (n = 380) | n = 286 | n = 94 | 0.03 |
 Prescribed oseltamivir (n) (%) | 180 (63%) | 71 (76%) |  |
 Not prescribed oseltamivir (n) (%) | 106 (37%) | 23 (24%) |  |